PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY MANTLE CELL LYMPHOMA

被引：0

作者：

Amin, A. ^{[1
]}

Taylor, R. ^{[2
]}

Alonso, A. ^{[3
]}

Schwenke, C. ^{[4
]}

Gaudig, M. ^{[5
,6
]}

Gaugris, S.

Welten, H. ^{[7
]}

Erhardt, W. ^{[8
]}

Roberts, G. ^{[1
]}

O'Leary, M. ^{[1
]}

Wasserman, M. ^{[9
]}

机构：

[1] Double Helix Consulting, London, England

[2] Univ Exeter, Sch Med, Exeter, Devon, England

[3] Maastricht Univ, Maastricht, Netherlands

[4] SCO SSiS, Berlin, Germany

[5] Janssen, EMEA Hlth Econ & Market Access, Neuss, Germany

[6] Janssen, Outcomes Res, High Wycombe, Bucks, England

[7] Janssen Cilag BV, Hlth Econ & Market Access, Tilburg, Netherlands

[8] Janssen Cilag GmbH, Hlth Econ & Market Access, Neuss, Germany

[9] Double Helix Consulting, Singapore, Singapore

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P456

引用

页码：147 / 148

页数：2

共 50 条

[1] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA
Amin, A.
Taylor, R.
Alonso, A.
Schwenke, C.
Gaudig, M.
Gaugris, S.
Welten, H.
Erhardt, W.
Roberts, G.
O'Leary, M.
Wasserman, M.
[J]. HAEMATOLOGICA, 2014, 99 : 591 - 591
[2] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
Dimopoulos M.
Sonneveld P.
Manier S.
Lam A.
Roccia T.
Schecter J.M.
Cost P.
Pacaud L.
Poirier A.
Tremblay G.
Lan T.
Valluri S.
Kumar S.
[J]. BMC Cancer, 24 (1)
[3] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Dimopoulos, M.
Sonneveld, P.
Nahi, H.
Kumar, S.
Hashim, M.
Kulakova, M.
Duran, M.
Heeg, B.
Lam, A.
Dearden, L.
[J]. VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
[4] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
Halabi, Susan
Rini, Brian
Escudier, Bernard
Stadler, Walter M.
Small, Eric J.
[J]. CANCER, 2014, 120 (01) : 52 - 60
[5] Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
Cicero, Giuseppe
De Luca, Rossella
Dieli, Francesco
[J]. ONCOTARGETS AND THERAPY, 2018, 11 : 3059 - 3063
[6] Assessment of Progression-free Survival as a Surrogate Endpoint for Overall Survival in Patients With Metastatic Renal Cell Carcinoma
Negrier, S.
Bushmakin, A. G.
Cappelleri, J. C.
Charbonneau, C.
Sandin, R.
Michaelson, M. D.
Figlin, R. A.
Motzer, R. J.
[J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S163 - S163
[7] Initial Salvage Approaches for Relapsed/Refractory Mantle Cell Lymphoma Have Comparable Response Rates, Progression-Free and Overall Survival
Caulfield, Sarah
Schlafer, Danielle
Switchenko, Jeffrey M.
Greenwell, Irl Brian
Staton, Ashley D.
Blum, Kristie A.
Grover, Natalie
Park, Steven I.
Danilov, Alexey
Epperla, Narendranath
Fenske, Timothy S.
Hamadani, Mehdi
Gordon, Max J.
Mathews, Stephanie
Valla, Kelly
Flowers, Christopher
Cohen, Jonathon B.
[J]. BLOOD, 2017, 130
[8] PROGRESSION-FREE SURVIVAL IS A ROBUST SURROGATE ENDPOINT OF OVERALL SURVIVAL IN IMMUNOTHERAPY TRIALS OF HEPATOCELLULAR CARCINOMA
Cabibbo, Giuseppe
Celsa, Ciro
Enea, Marco
Battaglia, Salvatore
Rizzo, Giacomo
Busacca, Anita
Matranga, Domenica
Attanasio, Massimo
Reig, Maria
Craxi, Antonio
Camma, Calogero
[J]. HEPATOLOGY, 2020, 72 : 649A - 649A
[9] Progression-free survival is a robust surrogate endpoint of overall survival in immunotherapy trials of hepatocellular carcinoma
Celsa, C.
Cabibbo, G.
Enea, M.
Battaglia, S.
Rizzo, G. E. M.
Busacca, A.
Matranga, D.
Attanasio, M.
Reig, M.
Craxi, A.
Camma, C.
[J]. DIGESTIVE AND LIVER DISEASE, 2021, 53 : S35 - S35
[10] Progression-free survival (PFS) as a surrogate for overall survival (OS)
Stewart, David J.
Bosse, Dominick
Hilton, John
Goss, Glenwood
Fung-Kee-Fung, Michael
Jonker, Derek
[J]. CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →